BioSpace News Archive

ASC Therapeutics has joined as a full partner the Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (AMP® BGTC) including the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), managed by the Foundation for the National Institutes of Health (FNIH).

Neurocrine Biosciences, Inc. announced that it has entered into separate, privately negotiated transactions with certain holders of its existing 2.25% Convertible Senior Notes due 2024 to repurchase approximately $179.4 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of an amount of cash estimated to be the sum of approximately $224.0 million, an amount based in part on the trading price of the Company’s common stock and accrued and unpaid interest.